Citius Oncology (CTOR) Institutional Ownership $1.87 -0.10 (-5.08%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Citius Oncology (NASDAQ:CTOR)CurrentInstitutional OwnershipPercentage70.52%Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$754.85KNumber ofInstitutional Sellers(last 12 months)0 Get CTOR Insider Trade Alerts Want to know when executives and insiders are buying or selling Citius Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CTOR Institutional Buying and Selling by Quarter Citius Oncology Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Bank of America Corp DE8,571$37K0.0%+5,256.9%0.011% 8/14/2025 Jane Street Group LLC106,970$465K0.0%N/A0.136% 8/8/2025 Geode Capital Management LLC57,297$249K0.0%+179.0%0.073% 8/4/2025 Arkadios Wealth Advisors11,666$51K0.0%N/A0.015% 2/17/2025 Citadel Advisors LLC22,699$26K0.0%N/A0.032% 2/4/2025 IFP Advisors Inc22,215$26K0.0%+173.1%0.031% (Data available from 1/1/2016 forward) CTOR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CTOR shares? During the previous two years, the following institutional investors and hedge funds held shares of Citius Oncology shares: Jane Street Group LLC ($465K), Geode Capital Management LLC ($249K), Arkadios Wealth Advisors ($51K), Bank of America Corp DE ($37K), and Citadel Advisors LLC ($26K), IFP Advisors Inc ($26K).Learn more on Citius Oncology's institutional investors. What percentage of Citius Oncology's stock is owned by institutional investors? 70.52% of Citius Oncology's stock is owned by institutional investors. Learn more on CTOR's institutional investor holdings. Which institutional investors have been buying Citius Oncology's stock? The following institutional investors have purchased Citius Oncology's stock in the last 24 months: Jane Street Group LLC ($106.97K), Geode Capital Management LLC ($36.76K), Citadel Advisors LLC ($22.70K), IFP Advisors Inc ($14.08K), Arkadios Wealth Advisors ($11.67K), and Bank of America Corp DE ($8.41K). How much institutional buying is happening at Citius Oncology? Institutional investors have bought a total of 200,584 shares in the last 24 months. This purchase volume represents approximately $754.85K in transactions. Related Companies Relay Therapeutics Institutional Ownership Rapport Therapeutics Institutional Ownership Keros Therapeutics Institutional Ownership Siga Technologies Institutional Ownership Rezolute Institutional Ownership Maravai LifeSciences Institutional Ownership Tourmaline Bio Institutional Ownership Xencor Institutional Ownership Gossamer Bio Institutional Ownership MeiraGTx Institutional Ownership This page (NASDAQ:CTOR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
